Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

591.60 +0.07 (+0.01%)
Official Closing Price Updated: 7:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
The study examined health care records for more than 41,000 people. 
Via Investor's Business Daily
Elliott Wave Technical Analysis: Eli Lilly & Co.
Looking for a triangle in wave (b) as we seem to be near the end of the correction. 
Via Talk Markets
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
A recent extensive analysis by Truveta Research has  
Via Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
Novo Nordisk A/S (NYSE: NVO) is reportedly discussing with healthcare systems to introduce innovative pricing arrangements for its popular weight  
Via Benzinga
$1000 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today
Via Benzinga
The Best Stocks to Invest $5,000 in Right Now
Here's how to safeguard your money and grow richer. 
Via The Motley Fool
Uncovering Noteworthy Technical Analysis Findings for ELI LILLY & CO (NYSE:LLY).
Promising Signs: ELI LILLY & CO Setting the Stage for a Breakout. 
Via Chartmill
3 Top Stocks That'll Make Smart Investors Rich
Long-term investing is one possible path to riches. 
Via The Motley Fool
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares. 
Via The Motley Fool
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
There's no time like the present to buy these stocks. 
Via The Motley Fool
Google Leads Five S&P 500 Stocks Near Buy Points
Four of the stocks tripped up after earnings, but quickly bounced back. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Could Ozempic Harm These 3 Medical Device Stocks?
The drug is on track to cause massive competitive shifts in the healthcare sector. 
Via The Motley Fool
Analyst Expectations for Eli Lilly's Future
Via Benzinga
A Look Into Eli Lilly Inc's Price Over Earnings
Via Benzinga
Eli Lilly Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years
Plug into a trio of megatrends with these three particular tickers. 
Via The Motley Fool
Will Eli Lilly Be Worth More Than Tesla by 2027?
It's a lot more likely than it sounds. 
Via The Motley Fool
3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape
Consider one of these three leading-edge healthcare stocks from companies focused on significant medical innovations. 
Via InvestorPlace
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
Could AstraZeneca be an under-rated buy right now? 
Via The Motley Fool
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
Via Benzinga
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. 
Via Benzinga
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now
Investors have favored an exciting billion-dollar opportunity at Eli Lilly. 
Via The Motley Fool
Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?
Eli Lilly just received FDA approval for its obesity medication Zepbound, the sister treatment to its blockbuster drug Mounjaro. 
Via The Motley Fool
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Relative Strength Index (RSI) Indicator: Does It Work?
The Relative Strength Index (RSI) is a contrarian technical analysis indicator that uses prices to find "overbought" and "oversold" assets. 
Via InvestorPlace
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
Goldman Sachs' 2024 Equity Outlook: Winning Stocks And Sectors To Watch
Dive into Goldman Sachs' 2024 Equity Outlook, detailing a positive forecast for the S&P 500, sector-specific strategies, and key stock picks for navigating a year of growth and stability. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.